Viracta Therapeutics Inc VIRX

NAS: VIRX | ISIN: US92765F1084 17:41

0,820 USD (+2,50%)

(+2,50%) 17:41

Grafiek Viracta Therapeutics Inc

Grafiek Viracta Therapeutics Inc

1 dag1d 2,50%
1 week1w 0,06%
1 maand1m -23,36%
3 maanden3m 46,42%
6 maanden6m 20,96%
1 jaar1j -7,85%
5 jaar5j -94,78%

Viracta Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

19 september 2022 · Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth · Persbericht

7 september 2022 · Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma · Persbericht

16 augustus 2022 · Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases · Persbericht

11 augustus 2022 · Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors · Persbericht

9 augustus 2022 · Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates · Persbericht

Profiel Viracta Therapeutics Inc

Website: www.sunesis.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: Dayton Misfeldt

Werknemers: 36

Aandelen Viracta Therapeutics Inc

Beurswaarde: 31,42 miljoen USD

Effecten: 39,27 miljoen

Beta: 0,92

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe